Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Avelumab + Azacitidine + PF-04518600 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Avelumab | Bavencio | MSB0010718C | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov). |
Azacitidine | Vidaza | azacytidine|CC-486|5-azacytidine|5-AC|U-18496|Onureg | DNMT inhibitor (Pan) 5 | Vidaza (azacitidine) is a cytidine analog that incorporates into DNA and RNA and binds to DNA methyltransferases (DNMTs), resulting in DNMT degradation and decreased DNA methylation, and leading to increased tumor cell death (PMID: 28159832, PMID: 28067760). Vidaza (azacitidine) is FDA-approved for use in patients with some subtypes of myelodysplastic syndrome and Onureg (azacitidine) is FDA approved for use in continued treatment of acute myeloid leukemia(FDA.gov). |
PF-04518600 | PF-8600|PF04518600|Ivuxolimab | OX40 Antibody 14 | PF-04518600 (Ivuxolimab) is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 3079-3079). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03390296 | Phase II | Avelumab + Azacitidine + PF-04518600 Azacitidine + PF-04518600 Avelumab + Utomilumab Avelumab + Glasdegib Gemtuzumab ozogamicin + Glasdegib PF-04518600 Avelumab + PF-04518600 PF-04518600 + Utomilumab | Pfizer Immunotherapy Combinations for Acute Myeloid Leukemia (AML) Multi-Arm Study 1 | Completed | USA | 0 |